贝伐珠单抗靶向治疗对晚期结直肠癌患者的临床疗效

Abstract: Objective To explore the clinical efficacy of bevacizumab targeted therapy in patients with advanced colorectal cancer. Methods Sixty-six patients with advanced colorectal cancer admitted to our hospital from January 2024 to May 2025 were selected. The patients were randomly divided into two groups, with 33 cases in each group, using the random number table method. The control group was given the conventional modified, sixth-edition combination chemotherapy regimen, while the observation group was additionally treated with bevacizumab injection. Collected and compared the treatment efficacy, tumor markers, immune indicator levels, and adverse reactions of the two groups. Results After treatment, the observation group had a higher effective rate compared to the control group (90.91% vs. 69.70%), with a significant difference (P＜0.05). The observation group had lower levels of tumor markers compared to the control group, with statistical significance (P＜0.05). After treatment, when comparing immune function between the two groups, the immune indicators of the observation group were higher than those of the control group, but there was no statistical difference. The incidence of adverse reactions in the observation group was not significantly different from that in the control group. Conclusion Bevacizumab combined with chemotherapy can reduce tumor cell activity by inhibition, but does not increase the incidence of adverse reactions, thus it can alleviate immune dysfunction and effectively control the progression of advanced colorectal cancer.